HELIOS-B
Vutrisiran Shows Promising Results in Phase 3 Study for ATTR-CM Treatment
Vutrisiran, ATTR-CM, Phase 3 Study, Alnylam Pharmaceuticals, HELIOS-B
Alnylam’s Vutrisiran Shows Promise in ATTR-CM Treatment, but Faces Competition
Alnylam, Vutrisiran, ATTR-CM, Phase 3 Trial, HELIOS-B, RNAi Therapeutics, Cardiomyopathy, Amyloidosis